IART, US4579852082

October 21 results set for Integra LifeSciences stock

Published on 10/17/2026 at 22:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue hit USD 418.76 million. Integra LifeSciences stock was USD 13.21 on October 16, 2026, down 2.37 percent versus Nasdaq's prior close.

Results date and valuation

Integra LifeSciences will release third-quarter results on October 21, 2026.
Second-quarter adjusted earnings per share reached USD 0.56 versus USD 0.48 expected.
Integra LifeSciences stock stood at USD 13.21 on October 16, 2026 at 4:00 p.m. ET, 2.37 percent below the Nasdaq prior close.
Market capitalization was USD 1.0 billion and the price-to-earnings ratio was minus 142.66.

IART, US4579852082, Illustration mit AI erstellt.

Integra LifeSciences will release its third-quarter 2026 results before the market opens on October 21, 2026, with a conference call at 8:30 a.m. ET, according to GlobeNewswire on October 6, 2026. The date gives investors a defined checkpoint for the company's revised outlook. Integra LifeSciences (US4579852082) last stood at USD 13.21 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, minus 2.37 percent versus the Nasdaq prior close.

Second-quarter figures

Integra reported second-quarter revenue of USD 418.76 million, compared with USD 417.54 million expected, while adjusted earnings per share reached USD 0.56 versus a USD 0.48 consensus estimate, according to Investing.com in its October 5, 2026 report. The revenue comparison points to a modest beat, but the upcoming release will show how the business performed after the company's October guidance update.

Price range and volume

The USD 13.21 price was 51.95 percent above the 52-week low of USD 8.70 and 35.53 percent below the 52-week high of USD 20.49. Trading volume reached 830,981 shares on October 16, 2026, against an average of 922,053 shares, or 90.12 percent of the average.

The latest price therefore sits nearer the lower end of the yearly range than the upper end. That placement matters because the October 21 results arrive after the company lowered its full-year outlook on October 2, 2026.

Valuation and calendar

Integra's market capitalization was USD 1.0 billion as of October 16, 2026. Its price-to-earnings ratio was minus 142.66, while its earnings per share were USD 2.36 on the same market-data date. The company has no reported dividend yield in the cited quote.

The next scheduled corporate event is the third-quarter release on October 21, 2026, before the Nasdaq open. Management's call is scheduled for 8:30 a.m. ET, according to GlobeNewswire.

Comparison with peers

Integra LifeSciences (Nasdaq, USD): minus 2.37 percent, P/E minus 142.66, market capitalization USD 1.0 billion
Medtronic (NYSE, USD): minus 0.73 percent, P/E 23.34, market capitalization USD 121.2 billion
Stryker (NYSE, USD): plus 0.49 percent, P/E 30.53, market capitalization USD 113.0 billion

Stock context

Integra's market value is a small fraction of the two larger medical-device companies in the comparison, while its negative price-to-earnings ratio reflects the latest earnings profile. The October 21 release will put the revised revenue and earnings outlook against completed quarterly figures.